Cellular uptake and intracellular fate of antisense oligonucleotides

Current Opinion in Molecular Therapeutics

Volumn 5, Issue 2, 2003, Pages 133-138

  Thierry, Alain R ^a   Vives, Eric ^a   Richard, Jean Philippe ^a   Prevot, Paul ^a   Martinand Mari, Camille ^a   Robbins, Ian ^a   Lebleu, Bernard ^a  

^a INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

Author keywords

Antisense oligonucleotides; Cellular uptake; Delivery vectors

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LIPID; RNA;

CHEMICAL MODIFICATION; DRUG DELIVERY SYSTEM; DRUG UPTAKE; GENE FUNCTION; INTERNALIZATION; INTRACELLULAR TRANSPORT; REVIEW;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; GENETIC VECTORS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0037799721     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Zamecnik PC, Stephenson ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA (11978) 75(1):280-284.
2. Crooke ST: Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta (1999) 1489(1):31-44.
3. Agrawal S, Kandimalla ER: Antisense therapeutics: Is it as simple as complementary base recognition? Mol Med Today (2000) 6(2):72-81.
4. Opalinska JB, Gewirtz AM: Nucleic-acid therapeutics: Basic principles and recent applications. Nat Rev Drug Discov (2002) 1(7):503-514.
5. Tuschl T: RNA interference and small interfering RNAs. Chembiochem (2001) 2(4):239-245.
6. Faria M, Giovannangeli C: Triplex-forming molecules: From concepts to applications. J Gene Med (2001) 3(4):299-310.
7. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA (1995) 92(13):5855-5859.
8. Cook DP: Medicinal chemistry of antisense oligonucleotides. In: Antisense Drug Technology. Crooke ST (Ed), Marcel Dekker Inc, New York, NY, USA (2001):29-56.
9. Lebedeva I, Stein CA: Antisense oligonucleotides: Promise and reality. Annu Rev Pharmacol Toxicol (2001) 41:403-419.
10. Stein CA: How to design an antisense oligodeoxynucleotide experiment: A consensus approach. Antisense Nucleic Acid Drug Dev (1998) 8(2):129-132.
11. Kang SH, Cho MJ, Kole R: Up-regulation of luciferase gene expression with antisense oligonucleotides: Implications and applications in functional assay development. Biochemistry (1998) 37(18):6235-6239.
12. Sazani P, Gemignani F, Kang SH, Maier MA, Manoharan M, Persmark M, Bortner D, Kole R: Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol (2002) 20(12):1228-1233.
13. Jen KY, Gewirtz AM: Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies. Stem Cells (2000) 18(5):307-319.
14. Juliano RL, Yoo H: Aspects of the transport and delivery of antisense oligonucleotides. Curr Opin Mol Ther (2000) 2(3):297-303.
15. Biessen EA, Vietsch H, Kuiper J, Bijsterbosch MK, Berkel TJ: Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. Mol Pharmacol (1998) 53(2):262-269.
16. Benimetskaya L, Loike JD, Khaled Z, Loike G, Silverstein SC, Cao L, el Khoury J, Cai TQ, Stein CA: Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nat Med (1997) 3(4):414-420.
17. Laktionov PP, Dazard JE, Vives E, Rykova EY, Piette J, Vlassov VV, Lebleu B: Characterisation of membrane oligonucleotide-binding proteins and oligonucleotide uptake in keratinocytes. Nucleic Acids Res (1999) 27(11):2315-2324.
18. de Diesbach P, N'Kuli F, Berens C, Sonveaux E, Monsigny M, Roche AC, Courtoy PJ: Receptor-mediated endocytosis of phosphodiester oligonucleotides in the HepG2 cell line: Evidence for non-conventional intracellular trafficking. Nucleic Acids Res (2002) 30(7):1512-1521.
19. de Diesbach P, N'Kuli F, Delmee M, Courtoy PJ: Infection by Mycoplasma hyorhinis strongly enhances uptake of antisense oligonucleotides: A reassessment of receptor-mediated endocytosis in the HepG2 cell line. Nucleic Acids Res (2003) 31(3):886-892.
20. Leonetti JP, Mechti N, Degols G, Gagnor C, Lebleu B: Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci USA (1991) 88(7):2702-2706.
21. Clarenc JP, Lebleu B, Leonetti JP: Characterization of the nuclear binding sites of oligodeoxyribonucleotides and their analogs. J Biol Chem (1993) 268(8):5600-5604.
22. Bennett CF, Chiang MY, Chan H, Shoemaker JE, Mirabelli CK: Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol (1992) 41(6):1023-1033.
23. Juliano RL, Alahari S, Yoo H, Kole R, Cho M: Antisense pharmacodynamics: Critical issues in the transport and delivery of antisense oligonucleotides. Pharm Res (1999) 16(4):494-502.
24. Miller PS, Ts'o PO: A new approach to chemotherapy based on molecular biology and nucleic acid chemistry: Matagen (masking tape for gene expression). Anticancer Drug Des (1987) 2(2):117-128.
25. Koppelhus U, Nielsen PE: Antisense properties of peptide nucleic acid (PNA). In: Antisense Drug Technology. Crooke ST (Ed), Marcel Dekker, New York, NY, USA (2001):359-374.
26. Vives E, Dell'Aquila C, Bologna JC, Morvan F, Rayner B, Imbach JL: Lipophilic pro-oligonucleotides are rapidly and efficiently internalized in HeLa cells. Nucleic Acids Res (1999) 27(20):4071-4076.
27. Leonetti JP, Machy P, Degols G, Lebleu B, Leserman L: Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication. Proc Natl Acad Sci USA (1990) 87(7):2448-2451.
28. Thierry AR, Dritschilo A: Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res (1992) 20(21):5691-5698.
29. Tavitian B, Marzabal S, Boutet V, Kuhnast B, Terrazzino S, Moynier M, Dolle F, Deverre JR, Thierry AR: Characterization of a synthetic anionic vector for oligonucleotide delivery using in vivo whole body dynamic imaging. Pharm Res (2002) 19(4):367-376.
30. Lavigne C, Thierry AR: Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system. Biochem Biophys Res Commun (1997) 237(3):566-571.
31. Rait AS, Pirollo KF, Xiang L, Ulick D, Chang EH: Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol Med (2002) 8(8):475-486.
32. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP: A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci USA (1995) 92(16):7297-7301.
33. Zelphati O, Szoka FJ: Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA (1996) 93(21):11493-11498.
34. Ryser HJ, Mandel R, Hacobian A, Shen WC: Methotrexate-poly(lysine) as a selective agent for mutants of Chinese hamster ovary cells defective in endocytosis. J Cell Physiol (1988) 135(2):277-284.
35. Lemaitre M, Bayard B, Lebleu B: Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site. Proc Natl Acad Sci USA (1987) 84(3):648-652.
36. Wagner E, Zenke M, Cotten M, Beug H, Birnstiel ML: Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc Natl Acad Sci USA (1990) 87(9):3410-3414.
37. Lollo, CP, Banaszczyk MG, Mullen PM, Coffin CC, Wu D, Cario AT, Bassett DL, Gouveia EK, Carlo DJ: Poly-L-lysine-based gene delivery systems. Synthesis, purification, and application. Methods Mol Med (2002) 69:1-13.
38. Derossi D, Joliot AH, Chassaing G, Prochiantz A: The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem (1994) 269(14):10444-10450.
39. Mann DA, Frankel AD: Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J (1991) 10(7):1733-1739.
40. Vives E, Brodin P, Lebleu B: A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem (1997) 272(25):16010-16017.
41. Lindsay MA: Peptide-mediated cell delivery: Application in protein target validation. Curr Opin Pharmacol (2002) 2(5):587-594.
42. Pooga M, Soomets U, Hallbrink M, Valkna A, Saar K, Rezaei K, Kahl U, Hao JX, Xu XJ, Wiesenfeld-Hallin Z, Hokfelt T et al: Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission In vivo. Nat Biotechnol (1998) 16(9):857-861.
43. Astriab-Fisher A, Sergueev DS, Fisher M, Shaw BR, Juliano RL: Antisense Inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem Pharmacol (2000) 60(1):83-90.
44. Astriab-Fisher A, Sergueev D, Fisher M, Shaw BR, Juliano RL: Conjugates of antisense oligonucleotides with the Tat and Antennapedia cell-penetrating peptides: Effects on cellular uptake, binding to target sequences, and biologic actions. Pharm Res (2002) 19(6):744-754.
45. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chemomordik LV, Lebleu B: Cell-penetrating peptides. A re-evaluation of the mechanism of cellular uptake. J Biol Chem (2003) 278(1):585-590.
46. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y: Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem (2001) 276(8):5836-5840.
47. Bijsterbosch MK, Manoharan M, Dorland R, Van Veghel R, Biessen EA, Van Berkel TJ: bis-Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides are highly selectively taken up by the liver. J Pharmacol Exp Ther (2002) 302(2):619-626.
48. Hoffmann AS: Hydrogels for biomedical applications. Adv Drug Deliv Rev (2002) 54(1):3-12.